medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2024, Number 1

<< Back

Rev Nefrol Dial Traspl 2024; 44 (1)

Kidney Health: The importance of primary care in health care and in reducing system costs

Del Amo M, Garriga M, Rosales W, Touceda L

Language: Spanish
References: 29
Page: 42-47
PDF size: 314.81 Kb.


ABSTRACT

Chronic Kidney Disease (CKD) is considered a public health problem with a high disease burden, affecting 9.1% of the world’s population (2017) with 1.2 million deaths annually.. In Argentina, the prevalence is estimated at 3.8 million cases, representing 12.7% of the population over 18 years of age. It is an asymptomatic disease and affects the population unequally, falling more heavily on the most vulnerable sectors. While premature mortality accounts for most of the disease burden, morbidity is also significant. Late treatment in advanced stages of the disease (dialysis and transplant) generates very high costs for the health system and significantly worsens people’s quality of life. The marked lack of knowledge of kidney disease in the population and the factors that could cause it contribute to its progression. It is commonly identified in advanced stages due to another ailment, apparently different from kidney disease and other comorbidities, generally cardiovascular conditions, which is why many patients die from associated pathologies without detecting CKD. The leading causes of CKD are modifiable, except age and other biological, genetic, or hereditary conditions. It is necessary to develop public health promotion and disease prevention policies to address risk factors and substantially reduce the disease burden.


REFERENCES

  1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ,Eckardt KU, et al. Chronic kidney disease as a globalpublic health problem: Approaches and initiatives - Aposition statement from Kidney Disease ImprovingGlobal Outcomes. Kidney Int. 2007;72(3):247–59.

  2. Schoolwerth AC, Engelgau MM, Hostetter TH, RufoKH, Chianchiano D, Mcclellan WM, et al. ChronicKidney Disease: A Public Health Problem That Needsa Public Health Action Plan. Clin J Am Soc Nephrol.2006;13(12):1779–80.

  3. Cortés-Sanabria L., Álvarez-Santana G., Orozco-González C., y otros. “Impacto económico de laenfermedad renal crónica: Perspectiva del InstitutoMexicano del Seguro Social”. Revista Médica delInstituto Mexicano del Seguro Social, 2017, vol. 55, 2:124-132.

  4. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A,Abebe M, et al. Global, regional, and national burdenof chronic kidney disease, 1990–2017: a systematicanalysis for the Global Burden of Disease Study 2017.Lancet. 2020;395(10225):709–33.

  5. Girard C, Diez R. Enfermedades renales en Argentina:¿Bajo el yugo de la nefroplutocracia? Revista NefrologíaArgentina, 2018;16:1–17.

  6. Crews DC, Bello AK, Saadi G. Burden, access, anddisparities in kidney disease. Arch Argent Pediatr.2019;117(3): E243–50.

  7. Curtis S, Sokoro A, Martin H, Mcleod L, ChartrandC, Lavallee B, et al. A Comprehensive QualityAssurance Platform in Canada for National Point-of-Care Chronic Kidney Disease Screening: The KidneyCheck Program. Kidney Int Reports. 2021;6(2):513–7.

  8. Peña M y Bacallao J. La obesidad en la pobreza: unnuevo reto para la salud pública. 2000.

  9. Alemano G, Celia E, Cusumano AM, Depine S. Guíade Práctica Clínica sobre Prevención y DetecciónPrecoz de la Enfermedad Renal Crónica en Adultosen el Primer Nivel de Atención. 2010;21.

  10. Gorostidi M, Santamaría R, Alcázar R, Fernández-Fresnedo G, Galcerán JM, Goicoechea M, et al.Documento de la sociedad española de nefrologíasobre las guías KDIGO para la evaluación yel tratamiento de la enfermedad renal crónica.Nefrología. 2014;34(3):302–16.

  11. Suarez L, Piaggio N, Simesen G, Bearzi L, LejtmanN, Chavez C, et al. Estudio multicéntrico deprevalencia de Enfermedad renal crónica. Rev NefrolArgentina. 2019;17(1):1–23.

  12. Kam-Tao Li P., Zhi-Hong L., y otros. TacklingDialysis Burden around the World: A GlobalChallenge. Kidney Diseases 2021; 7:167–175.

  13. Erikson K., Zhao B., Ho V., y Winkelmayer W.Employment among Patients Starting Dialysis inthe United States. Clinical Journal of the AmericanSociety of Nephrology, Vol 13 February 2018: 265-273y Appendix.

  14. Bacqué MC, Vallejos A y Bisigniano L. Situacióndel trasplante renal y la donación de órganos enArgentina. Rev Nefrol Dial Traspl. 2018; 38 (1): 1-14.

  15. Torregosa JV, Bover J, Rodriguez Portillo M, GonzalezParra E, Arenas MD, Caravaca F, Gonzalez Casaus ML,Malo AM, Navarro Gonzalez JF, Lorenzo V, Molina P,Rodriguez M y Cannata Andia J. Recomendacionesde la Sociedad Española de Nefrología para el manejode las alteraciones del metabolismo óseo- mineralen los pacientes con enfermedad renal crónica:2021 (SEN-MM). Revista de la Sociedad Española deNefrología 2022; 42(S3): 1-37.

  16. Bezerra da Silva G., Gomes Ramalho de Oliveira J.,Barros de Oliveira R., y otros. Global costs attributedto chronic kidney disease: a systematic review. Rev.Assoc. Med. Bras. 2018; 64(12):1108-1116.

  17. Damien P., Lanham H., Parthasarathy M., y ShahN. Assessing key cost drivers associated with caringfor chronic kidney disease patients. BMC HealthServices Research (2016) 16:690.

  18. Lorenzo-Sellares V., Pedrosa I., Santana-ExpósitoB., y otros. Análisis de costes y perfil socioculturaldel enfermo renal. Impacto de la modalidad detratamiento. Revista Nefrología, 2014;34(4):458-68.

  19. Karopadi A., Mason G., Rettore E., y Ronco C. Costof peritoneal dialysis and haemodialysis across theworld. Nephrol Dial Transplant 2013, 28:2553–2569.

  20. Karopadi A., Mason G., Rettore E., y Ronco C. Therole of economies of scale in the cost of dialysis acrossthe world: a macroeconomic perspective. NephrolDial Transplant, 2014 Apr;29(4):885-892

  21. Himmelfarb J., Vanholder R., Mehrotra R., yTonelli M. The current and future landscape ofdialysis. Nature Reviews Nephrology, 2020, Volume16:573–585.

  22. Torales S., Berardo J., Hasdeu S., Esquivel M.,Rosales A., Azofeifa C. et al. Evaluación económicacomparativa sobre terapias de reemplazo renalen Argentina, Costa Rica y Uruguay. RevistaPanamericana de Salud Pública 2021; 45: e119.

  23. Vanholder R., Davenport A., Hannedouche T., yotros. Reimbursement of Dialysis: A Comparisonof Seven Countries. Journal of American Society ofNephrology, 23 (2012):1291–1298.

  24. Piwko C., Vicente C., Marra L, y otros (2012).The STARRT trial: a cost comparison of optimal vssub-optimal initiation of dialysis in Canada. Journalof Medical Economics Vol. 15, No. 1, 2012: 96–104.

  25. Cheo SW, Low QJ, Lim TH, Mak WW, Yip CAK,Wong KW. A practical approach to chronic kidneydisease in primary care. Malays Fam Physician. 2022Mar 2;17(1):10-19. doi: 10.51866/rv1186

  26. Levey AS, Schoolwerth AC, Burrows NR, etal. Comprehensive Public Health Strategies forPreventing the Development, Progression, andComplications of CKD: Report of an Expert PanelConvened by the Centers for Disease Control andPrevention. American Journal of Kidney Diseases, Vol53, No 3 (March), 2009: pp 522-535.

  27. Levin A, Adams E, Barrett BJ, Beanlands H, BurnsKD, Chiu HH, et al. Canadians Seeking Solutionsand Innovations to Overcome Chronic KidneyDisease (Can-SOLVE CKD): Form and Function.Canadian Journal of Kidney Health and Disease,2020,Volume 5: 1 –12

  28. Torales S, Vallejos A, Valenti L. Hacia un nuevoparadigma en el abordaje de la enfermedad renalcrónica avanzada. Rev. Argentina Salud Pública.2018;9(35):33–7.

  29. Banco Mundial. Los años no vienen solos: oportunidadesy desafíos económicos de la transición demográfica enArgentina. 2014.




2020     |     www.medigraphic.com